Serelaxin, recombinant human relaxin-2, for heart failure patients: A systematic review and meta-analysis

BACKGROUND: Serelaxin, recombinant human relaxin-2, is a hormone with vasodilatory and end-organ protective effects. Recently, it has been licensed to treat acute decompensated heart failure. Here, a systematic review and meta-analysis on randomized controlled trials (RCTs) was performed to assess t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Ling, Cao, Lijuan, Sun, Jing, Li, Zhongyi, Yao, Fengzhen, Zhou, Yabin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023957/
https://www.ncbi.nlm.nih.gov/pubmed/29923986
http://dx.doi.org/10.1097/MD.0000000000011010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023957/
https://www.ncbi.nlm.nih.gov/pubmed/29923986
http://dx.doi.org/10.1097/MD.0000000000011010

Ejemplares similares